BioNTech, Bristol Myers Report 36.7% Response Rate in NSCLC Trial
BioNTech and Bristol Myers Squibb reported a 36.7% response rate for the pumitamig combination in a Phase II second-line NSCLC trial.
BioNTech and Bristol Myers Squibb reported a 36.7% response rate for the pumitamig combination in a Phase II second-line NSCLC trial.